As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.
27 Analysts have issued a Arvinas, Inc. forecast:
27 Analysts have issued a Arvinas, Inc. forecast:
Jun '25 |
+/-
%
|
||
Revenue | 373 373 |
73%
73%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -112 -112 |
81%
81%
|
EBIT (Operating Income) EBIT | -119 -119 |
80%
80%
|
Net Profit | -73 -73 |
86%
86%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.
Head office | United States |
CEO | John Houston |
Employees | 430 |
Founded | 2013 |
Website | www.arvinas.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.